ES-Lomac D SR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying or gastroparesis. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief and promoting healing in acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. ES-Lomac D SR Capsule is indicated for patients requiring combined prokinetic and acid suppression therapy, particularly in cases where acid reflux is accompanied by impaired gastric motility. It should be administered under medical supervision, with caution advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or hepatic impairment. Potential side effects include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms. This combination therapy offers a comprehensive approach to managing complex upper gastrointestinal conditions by addressing both acid secretion and motility disturbances.